CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Finland's Revenio Q3 net sales jump after Visionix consolidation

By Reuters News


Overview

  • Finland eye care device maker's Q3 net sales rose 128% yr/yr after Visionix consolidation

  • Q3 adjusted EBITA margin fell to 14.7% from 25.7%, reflecting Visionix's lower margin profile

  • Company narrowed 2026 net sales guidance to EUR 190-200 mln, citing softer market conditions


Outlook

  • Revenio sees 2026 exchange rate-adjusted net sales between EUR 190 mln and EUR 200 mln

  • Company maintains guidance for adjusted EBITA-% at a satisfactory level for 2026

  • Revenio says lower end of outlook assumes continued softness in market demand and slower customer activity


Result Drivers

  • VISIONIX CONSOLIDATION - Q3 results reflect first full quarter with Visionix, driving sharp increase in net sales but lowering overall margin profile

  • REGIONAL SALES VARIATION - Strong sales in EMEA and LATAM, especially France and Italy, offset by challenging APAC market and North America decline due to sales team reorganization

  • TARIFF REFUNDS - Gross margin benefited from tariff refunds related to North American business


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

EUR 58.80 mln

Q3 EPS

EUR 0.12

Q3 EBIT

EUR 3.60 mln

Q3 EBITDA

EUR 7.30 mln

Q3 ROE

2.20%


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for Revenio Group Oyj is €13.60, about 34.9% above its November 11 closing price of €10.08

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 12 - Finland's Bioretec Q3 sales rise on repeat surgeon utilization, KOL network growth

  • Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

  • Nov 12 - Switzerland's Sonova H1 revenue rises, lifts FY outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.